Tianjin KMD Bioscience Co., Ltd. has been committed to becoming a leading provider of therapeutic antibody discovery and related support services since its establishment in 2022. Focusing on technological research and development, the company provides high-quality Contract Research Organization (CRO) services to scientists and research institutions worldwide, aiming to promote the development and innovation of medical science and technology. As a high-tech enterprise, it has been recognized as a National Patent Pilot Unit and obtained ISO9001:2015 Quality Management System certification for its laboratories. The company has been granted more than 30 patents and 4 registered trademarks. Over 90% of the technical service team members hold a master’s degree or higher. Each year, the company offers nearly a thousand technical service consultations, solution designs, and project deliveries to various research institutions, hospitals, pharmaceutical companies, and biotechnology firms domestically and internationally. Its core service platforms include: Antibody Drug Discovery Platform, Antibody Engineering and Optimization Platform, Stable Cell Line Development and Microbial Strain Engineering Platform, Recombinant Antibody and Protein Expression and Purification Platform.